Lucentis
Scope
Date
~
-
Bio & PharmaSamsung Bioepis gets FDA OK for its interchangeable biosimilar
Byooviz, a biosimilar of the macular degeneration treatment Lucentis and made by South Korea’s Samsung Bioepis, has received official design...
Oct 25, 2023 (Gmt+09:00)
-
Bio & PharmaSamsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
BiosimilarsSamsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz
Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...
Sep 23, 2021 (Gmt+09:00)
-
BiosimilarsSamsung Bioepis gets nod for sale of ophthalmology biosimilar in Europe
South Korea’s biopharmaceutical company Samsung Bioepis Co. won approval from European authorities for sale of Byooviz, its ophthalmology bios...
Aug 23, 2021 (Gmt+09:00)
language
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand
